PepGen Abandons Duchenne Program, Shifts Spotlight To Another Rare Disease Candidate

1. PepGen discontinued PGN-EDO51 for Duchenne muscular dystrophy due to unsatisfactory results. 2. Favorable safety profile observed, but dystrophin levels were inadequate. 3. Focus will shift to advancing DM1 program with ongoing Phase 2 clinical trials. 4. Upcoming data expected from FREEDOM-DM1 and FREEDOM2-DM1 studies in 2025 and 2026. 5. PEPG stock fell 6.69% following the announcement.